We provided more than 129 million doses of VERMOX® (mebendazole), our treatment for intestinal worms, to infected children in 14 countries in 2015.
In 2015, 80 Johnson & Johnson products were recognized by Earthwards®, our internal program that encourages the development of innovative and more-sustainable products.
92% of our employees have completed a health risk assessment and know their key health indicators.
Approximately 98% of our strategic suppliers have two or more publicly-reported sustainability goals.
In more than 100 countries, our HIV medicines are made available either at special-effort or reduced pricing.
170 of our major philanthropic programs reported measuring long-term outputs and/or outcomes in 2015.
Advance Global Health
Steward a Healthy Environment
Engaged, Health-Conscious Employees
Access to HIV Medicines
Share Product Sustainability Information
In 2016, Johnson & Johnson ranked second on this biennial index, which measures pharmaceutical company factors affecting access to medicines.
In 2016, Barron’s recognized Johnson & Johnson as the world’s most respected company, based on its annual survey of institutional investors.
Fortune Magazine recognized Johnson & Johnson as the 15th most-admired company overall and number one in pharmaceuticals in 2016.
Johnson & Johnson was ranked 8th by the Corporate Knights in their 2017 index of the Global 100 Sustainable Companies.
For the 6th consecutive year, Practice Greenhealth recognized Johnson & Johnson as a “Champion for Change” in healthcare environmental sustainability practices.
In 2016, the CDP (formally the Carbon Disclosure Project) ranked Johnson & Johnson first in health care.
Johnson & Johnson placed 11th in the U.S. and 19th globally in Newsweek’s 2016 Green Rankings.
IW Financial ranked Johnson & Johnson 4th in the 2016 Corporate Responsibility Magazine 100 Best Corporate Citizens Index.
Access to Medicines Index
Corporate Responsibility Magazine